OCUGEN, INC. Payments for Repurchase of Initial Public Offering
OCUGEN, INC. (OCGN) reported Payments for Repurchase of Initial Public Offering of $2.49 million for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2016-03-10
- OCUGEN, INC. payments for repurchase of initial public offering for the quarter ending 2014-12-31 was $1.04M.
- OCUGEN, INC. payments for repurchase of initial public offering for the quarter ending 2014-09-30 was $804.00K.
- OCUGEN, INC. payments for repurchase of initial public offering for the quarter ending 2014-06-30 was $404.00K.
- OCUGEN, INC. payments for repurchase of initial public offering for the quarter ending 2014-03-31 was $235.00K.
- OCUGEN, INC. payments for repurchase of initial public offering for fiscal 2014 was $2.49M.
| Period end | Payments for Repurchase of Initial Public Offering 3 month | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 9 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|---|---|
| 2014-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $1.85M derived: sum of 2 quarters · filed 2016-03-10 | $2.25M derived: sum of 3 quarters · filed 2016-03-10 | $2.49M 10-K · filed 2016-03-10 |
| 2014-09-30 | $804.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $1.21M derived: sum of 2 quarters · filed 2015-11-12 | $1.44M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $404.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $639.00K 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | $235.00K 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |